Vitamin D Headlines (5.9.2025)
Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy.
Read Article
International Myositis Assessment and Clinical Studies Group (IMACS) reached a consensus on ‘anti-synthetase syndrome’ as the preferred nomenclature and "ASyS" as the preferred abbreviation for the ‘anti-synthetase syndrome. https://t.co/TuTzVVZzZO https://t.co/qs5f1qATKi
Dr. John Cush @RheumNow( View Tweet )
Immune Checkpoint Inhib causing Myasthenia Gravis w/ poor outcomes - 16 ICI Rx pts (9 Lung CA, 7 other tumors) Dx w/ MG; 11 w/ overlap myositis. Mean onset @ 49d. All Rx wp steroids, 6 immunosuppressives, 5 plasma exchange; only 2 complete resp. 6 deaths re: MG complications https://t.co/re73lh2Xfs
Dr. John Cush @RheumNow( View Tweet )
Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/Oi91niMn5M
Dr. John Cush @RheumNow( View Tweet )
Immune Checkpoint Inhib causing Myasthenia Gravis w/ poor outcomes - 16 ICI Rx pts (9 Lung CA, 7 other tumors) Dx w/ MG; 11 w/ overlap myositis. Mean onset @ 49d. All Rx wp steroids, 6 immunosuppressives, 5 plasma exchange; only 2 complete resp. 6 deaths re: MG complications https://t.co/PUc6kIE7FW
Dr. John Cush @RheumNow( View Tweet )
Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/PvtmVCv2QJ
Dr. John Cush @RheumNow( View Tweet )
Cancer Survival with TNF Inhibitors (3.28.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Read Article
An Unusual Consult for Myopathy
Presentation by Dr. Kelsey Lemmen, at the Rheumatology Winter Clinical Symposia - Feb 2025
https://t.co/DYlzee6qcs https://t.co/nUxTC9roF9
Dr. John Cush @RheumNow( View Tweet )
FDA grants priority reviews to:
- Nicalizumab (J&J; FcRn antibody) for use in Myasthenia gravis.
- Upadacitinib (AbbVie; JAK inhib) for use in GCA
- Namistat (BI: PDE4B inhib) for use in Idiopathic pulmonary fibrosis
- Inalizumab (Hansen; anti-CD19) for use in IG4 rel Dz
-… https://t.co/dsg9vZASrk https://t.co/8t2USASmm8
Dr. John Cush @RheumNow( View Tweet )
JAMA Case: A Woman With Painful Digital Ulcers - What would you order next?
- chest CT w/ myositis-specific autoAb panel
- dsDNA
- SCL-70 & Centromere Abs
- muscle biopsy https://t.co/t0WCIMtZg2 https://t.co/M1jBhnclLl
Dr. John Cush @RheumNow( View Tweet )
Opioid Deaths are Down (2.28.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Opioid deaths are down, IL-33 levels are up and Weight loss is in the news again this week!
Read Article
Misdiagnosis of Dermatomyositis
JAMA Dermatology reports a retrospective cohort study from Johns Hopkins reviewing mimic of dermatomyositis (DM), suggesting that DM and especially clinically amyopathic DM (CADM) are commonly and initially misdiagnosed as inflammatory skin disease (ISD).
The study was undertaken to
Read Article
JAMA Case: A Woman With Painful Digital Ulcers - What would you order next?
- chest CT w/ myositis-specific autoAb panel
- dsDNA
- SCL-70 & Centromere Abs
- muscle biopsy https://t.co/9T8mNDdJTs https://t.co/pTphzcuZKF
Dr. John Cush @RheumNow( View Tweet )
Risk Prediction Modeling in MDA5 Dermatomyositis
Patients with Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) are complicated and prone to interstitial lung disease, poor prognosis, and a high mortality. A new study suggests a risk prediction… https://t.co/v20ZCVZUQE https://t.co/GmWWQDpWUU
Dr. John Cush @RheumNow( View Tweet )
Risk Prediction Modeling in MDA5 Dermatomyositis
Patients with Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) are complicated and prone to interstitial lung disease, poor prognosis, and a high
Valentine RNL 2025 Review (2.14.2025)
Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.
Read Article
Facing challenges in diagnosing idiopathic inflammatory myopathies? Check out our recent webinar to hear from Stanley J. Naides, MD, FACP, FACR, as he explores the role of autoantibody testing in autoimmune myositis diagnosis and phenotyping. Sponsored by LabCorp Rx. #Myositis… https://t.co/4jMevolO3k https://t.co/ObWPR8QFW2
Dr. John Cush @RheumNow( View Tweet )
Dazukibart Effective in Adults with Dermatomyositis
Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).… https://t.co/7oRyxrFpar https://t.co/wA06Kzsdqg
Dr. John Cush @RheumNow( View Tweet )
QD Clinic - Treating Overlap with ILD
Polyarthritis, ILD, Dermatomyositis - how to treat?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6
https://t.co/CsIpdS8hyd https://t.co/I92p5U3UTp
Dr. John Cush @RheumNow( View Tweet )
Fallen Angels (1.17.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.
Read Article
RheumThoughts: Overlap Syndrome with ILD
How would you manage a patient with Overlap (anti-synthetase) syndrome, ILD, polyarthritis and myositis?
https://t.co/4RyV1zkphe https://t.co/qTZ4JYlJmW
Dr. John Cush @RheumNow( View Tweet )
Dazukibart Effective in Adults with Dermatomyositis
Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).
Read Article
Nipocalimab, a mAb that blocks FcRn, was granted a Priority Review from the FDA. J&J has submitted Biologics License Application (BLA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) myasthenia gravis based on Phase 3 Vivacity-MG3 study.… https://t.co/6sVbrgTBvF https://t.co/9a1dBWz87R
Dr. John Cush @RheumNow( View Tweet )
Retrospectively review of 165 #EGPA pts, GI manifestations were assoc w/ Eosinophils > 19.5%, weight loss, & myalgia; & included abdominal pain (78%), diarrhea (40%), N/V (33%); GI hemorrhage (27%), ulcers (17%), obstruction (10%), & pancreatitis (6%) https://t.co/EzsGcFs2l2 https://t.co/mQrgjTG6NV
Dr. John Cush @RheumNow( View Tweet )
Bah Humbug Vitamin D (12.20.2024)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read ArticleRecent Blogs
Winning is everything – in football and in medicine. Rheumatologists have achieved many successes but still struggle to win against a handful of rheumatic foes. This retrospective examines past wins and losses and helps us to look ahead to a new season.
Read Post
